C. Leonardi

发表

The tumour necrosis factor‐α inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques

K. Gordon, B. Nickoloff, B. Bonish, 2005, The British journal of dermatology.

Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR)

L. Ferris, E. Muñoz-Elías, A. Blauvelt, 2017, The British journal of dermatology.

The safety of ustekinumab treatment in patients with moderate‐to‐severe psoriasis and latent tuberculosis infection

M. Song, Y. Wasfi, Y. Shen, 2012, The British journal of dermatology.

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)

T. Luger, U. Mrowietz, R. Bissonnette, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis

B. Strober, B. Elewski, A. Gottlieb, 2007, The British journal of dermatology.

Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis

K. Gordon, A. Nader, R. Gniadecki, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Long‐term efficacy and safety of risankizumab for the treatment of moderate‐to‐severe plaque psoriasis: interim analysis of the LIMMitless open‐label extension trial beyond 3 years of follow‐up

M. Lebwohl, A. Soliman, K. Papp, 2021, The British journal of dermatology.

A phase I/II randomized, double‐blind, placebo‐controlled, dose‐ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

C. Leonardi, Ak Gupta, RR Stoltz, 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks

A. Gottlieb, R. Krishnan, D. Cella, 2007, The British journal of dermatology.

Rapid improvements in health‐related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER‐2 and UNCOVER‐3

R. Burge, M. Gooderham, K. Reich, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate‐to‐severe plaque psoriasis

K. Reich, L. Mallbris, L. Puig, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5‐year data from reSURFACE 1 and reSURFACE 2

M. Lebwohl, N. Mehta, M. Gooderham, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

A high level of clinical response is associated with improved patient‐reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab

W. Shen, E. Edson-Heredia, K. Gordon, 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

Nail Outcome Improvements with Certolizumab Pegol in Moderate to Severe Plaque Psoriasis: Results from Phase 3 Trials

A. Gottlieb, K. Reich, Y. Poulin, 2019, SKIN The Journal of Cutaneous Medicine.

Efalizumab‐induced autoimmune pancytopenia

W. Tom, C. Leonardi, M. Hurley, 2006, The British journal of dermatology.